- Home
- CHCO vs KURA Comparison
CHCO vs KURA Comparison
Compare CHCO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCO
- KURA
- Stock Information
- Founded
- CHCO 1957
- KURA 2014
- Country
- CHCO United States
- KURA United States
- Employees
- CHCO N/A
- KURA N/A
- Industry
- CHCO Major Banks
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHCO Finance
- KURA Health Care
- Exchange
- CHCO Nasdaq
- KURA Nasdaq
- Market Cap
- CHCO 1.7B
- KURA 1.5B
- IPO Year
- CHCO N/A
- KURA N/A
- Fundamental
- Price
- CHCO $114.66
- KURA $18.04
- Analyst Decision
- CHCO Hold
- KURA Strong Buy
- Analyst Count
- CHCO 3
- KURA 6
- Target Price
- CHCO $104.67
- KURA $30.60
- AVG Volume (30 Days)
- CHCO 54.1K
- KURA 473.0K
- Earning Date
- CHCO 10-22-2024
- KURA 10-31-2024
- Dividend Yield
- CHCO 2.74%
- KURA N/A
- EPS Growth
- CHCO 1.10
- KURA N/A
- EPS
- CHCO 7.76
- KURA N/A
- Revenue
- CHCO $287,617,000.00
- KURA N/A
- Revenue This Year
- CHCO N/A
- KURA N/A
- Revenue Next Year
- CHCO $0.65
- KURA N/A
- P/E Ratio
- CHCO $14.84
- KURA N/A
- Revenue Growth
- CHCO 2.36
- KURA N/A
- 52 Week Low
- CHCO $86.56
- KURA $7.41
- 52 Week High
- CHCO $125.54
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- CHCO 45.24
- KURA 31.37
- Support Level
- CHCO $112.52
- KURA $19.99
- Resistance Level
- CHCO $118.56
- KURA $19.94
- Average True Range (ATR)
- CHCO 2.29
- KURA 0.71
- MACD
- CHCO -0.54
- KURA -0.24
- Stochastic Oscillator
- CHCO 20.27
- KURA 0.30
About CHCO City Holding Company
City Holding Co is a financial holding company. It provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, saving accounts, credit card and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance, technology products, and others. These products and services are provided to commercial banking, consumer banking, mortgage banking, wealth management, and trust services.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.